Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update!

$Vincerx Pharma(VINC.US)$ Vincerx Pharma Presents Preliminary Phase 1 Data For VIP236 And Updates On Pipeline Progress At AACR Annual Meeting 2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors
VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically
In preclinical studies, Vincerx's next-generation effector chemistry improves the efficacy of two approved antibody-drug conjugates (ADCs), highlighting VersAptx platform's potential to advance cancer therapies
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
1
+0
9
Translate
Report
6971 Views
Comment
Sign in to post a comment
2003Followers
31Following
24KVisitors
Follow